厄贝沙坦氢氯噻嗪片治疗原发性高血压的临床疗效及安全性

Clinical effect and safety of irbesartan hydrochlorothiazide in the treatment of primary hypertension

目的 观察厄贝沙坦氢氯噻嗪片治疗原发性高血压的临床疗效及安全性。方法 选取2019年4月-2021年3月上犹县中医院收治的80例原发性高血压患者为研究对象,采用随机数字表法分为对照组和研究组,各40例。对照组予以非洛地平治疗,研究组予以厄贝沙坦氢氯噻嗪治疗,2组均持续治疗28 d。比较2组临床疗效,治疗前后血压[舒张压(DBP)、收缩压(SBP)、平均动脉压(MAP)]、血清指标[白介素6 (IL-6)、C反应蛋白(CRP)、一氧化氮(NO)及超氧化物歧化酶(SOD)]、血流动力学指标[全血低切黏度(LRV)、全血高切黏度(HRV)、血浆黏度(PV)],不良反应。结果 研究组总有效率为95.00%,高于对照组的80.00%(χ^(2)=4.114,P=0.043)。治疗后,2组DBP、SBP、MAP低于治疗前,且研究组低于对照组(P<0.01)。2组血清IL-6、CRP水平低于治疗前,血清NO、SOD水平高于治疗前,且研究组血清IL-6、CRP水平低于对照组,血清NO、SOD水平高于对照组(P<0.01)。2组治疗前后血浆LRV、HRV、PV比较,差异无统计学意义(P>0.05)。研究组治疗期间不良反应总发生率为10.00%,低于对照组的27.50%(χ^(2)=4.021,P=0.045)。结论 厄贝沙坦氢氯噻嗪治疗原发性高血压患者的临床疗效确切,可有效降低血压,减轻炎性反应,改善血管内皮功能,并不会对患者血流动力学产生影响,且安全性较高。

Objective To observe the clinical effect and safety of irbesartan hydrochlorothiazide in the treatment of primary hypertension.Methods A total of 80 cases of primary hypertension patients were selected from April 2019 to March2021 in Shangyou County Traditional Chinese Medicine Hospital,and they were divided into control group and study group according to random number table method,40 cases in each group.Patients in control group were given felodipine,and patients in study group were given irbesartan hydrochlorothiazide,both groups were treated for 28 d.Clinical effect,blood pressure(DBP,SBP,MAP),serum indexes(IL-6,CRP,NO,SOD),hemodynamic indexes(LRV,HRV,PV) before and after treatment,incidence of adverse reactions were compared between the two groups.Results Total effective rate in study group was 95.00%,which was higher than 80.00%of control group(χ^(2)=4.114,P=0.043).After treatment,DBP,SBP,MAP in the two groups were lower than those before treatmemt,and those in study group were lower than control group(P<0.01).Serum levels of IL-6,CRP in the two groups were lower than those before treatment,serum levels of NO,SOD were higher than those before treatment,and the serum levels of IL-6,CRP in study group were lower than those in control group,serum levels of NO,SOD were higher than those in control group(P<0.01).There was no significant difference of blood plasma of LRV,HRV,PV before and after treatment between the two groups(P>0.05).Incidence of adverse reactions in study group was 10.00%,which was lower than 27.50%of control group(χ^(2)=4.021,P=0.045).Conclusion Irbesartan hydrochlorothiazide has an exact clinical effect in the treatment of primary hypertension,can decrease blood pressure,reduce inflammatory reaction,improve vascular endothelial function,has no impact on the hemodynamics of patients,and with higher safety.